Cargando…
Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice
BACKGROUND: Diabetes mellitus is a chronic metabolic disorder that imposes a huge health and economic burden on societies. Because the currently available medications have many drawbacks, it is important to search for alternative therapies. Medicinal plants used in traditional medicines are ideal ca...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039073/ https://www.ncbi.nlm.nih.gov/pubmed/32110120 http://dx.doi.org/10.2147/JEP.S240266 |
_version_ | 1783500754673205248 |
---|---|
author | Alema, Niguse Meles Periasamy, Gomathi Sibhat, Gereziher Gebremedhin Tekulu, Gebretsadkan Hintsa Hiben, Mebrahtom Gebrelibanos |
author_facet | Alema, Niguse Meles Periasamy, Gomathi Sibhat, Gereziher Gebremedhin Tekulu, Gebretsadkan Hintsa Hiben, Mebrahtom Gebrelibanos |
author_sort | Alema, Niguse Meles |
collection | PubMed |
description | BACKGROUND: Diabetes mellitus is a chronic metabolic disorder that imposes a huge health and economic burden on societies. Because the currently available medications have many drawbacks, it is important to search for alternative therapies. Medicinal plants used in traditional medicines are ideal candidates. Hence, this study was undertaken to investigate the antidiabetic activity of crude extract and solvent fractions from the stem bark of Terminalia brownii Fresen. (Combretaceae) in mice. MATERIALS AND METHODS: The in vitro α-amylase inhibition assay was performed using the chromogenic 3, 5-dinitrosalicylic acid (DNSA) method while the antihyperglycemic activity was assessed using three mouse models: streptozotocin-induced diabetic mice, normoglycemic mice, and oral glucose challenged mice. Experimental diabetes was induced by a single intraperitoneal injection of streptozotocin at a dose of 150 mg/kg and animals with fasting blood glucose level (BGL) >200 mg/dL were considered diabetic. Glibenclamide (5 mg/kg) was used as a standard drug. Fasting BGL and body weight were used to assess the antidiabetic activity. The result was analyzed using GraphPad Prism software version 8 and one-way ANOVA followed by Tukey’s post hoc test with p<0.05 considered as statistically significant. RESULTS: The crude extract of T. brownii at all tested dose levels (250, 500 and 750 mg/kg) showed a significant BGL reduction in all the three animal models. Moreover, the ethyl acetate and aqueous fractions (at 500 mg/kg) significantly (p<0.01) reduced the BGL in the streptozotocin induced diabetic model. The crude extract and different solvent fractions also showed a dose-dependent in vitro α-amylase inhibitory activity and improvement of body weight. CONCLUSION: T. brownii crude extract and its solvent fractions showed a significant antihyperglycemic activity in STZ induced diabetic mice, hypoglycemic activity and improvement of oral glucose tolerance in normal mice. |
format | Online Article Text |
id | pubmed-7039073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-70390732020-02-27 Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice Alema, Niguse Meles Periasamy, Gomathi Sibhat, Gereziher Gebremedhin Tekulu, Gebretsadkan Hintsa Hiben, Mebrahtom Gebrelibanos J Exp Pharmacol Original Research BACKGROUND: Diabetes mellitus is a chronic metabolic disorder that imposes a huge health and economic burden on societies. Because the currently available medications have many drawbacks, it is important to search for alternative therapies. Medicinal plants used in traditional medicines are ideal candidates. Hence, this study was undertaken to investigate the antidiabetic activity of crude extract and solvent fractions from the stem bark of Terminalia brownii Fresen. (Combretaceae) in mice. MATERIALS AND METHODS: The in vitro α-amylase inhibition assay was performed using the chromogenic 3, 5-dinitrosalicylic acid (DNSA) method while the antihyperglycemic activity was assessed using three mouse models: streptozotocin-induced diabetic mice, normoglycemic mice, and oral glucose challenged mice. Experimental diabetes was induced by a single intraperitoneal injection of streptozotocin at a dose of 150 mg/kg and animals with fasting blood glucose level (BGL) >200 mg/dL were considered diabetic. Glibenclamide (5 mg/kg) was used as a standard drug. Fasting BGL and body weight were used to assess the antidiabetic activity. The result was analyzed using GraphPad Prism software version 8 and one-way ANOVA followed by Tukey’s post hoc test with p<0.05 considered as statistically significant. RESULTS: The crude extract of T. brownii at all tested dose levels (250, 500 and 750 mg/kg) showed a significant BGL reduction in all the three animal models. Moreover, the ethyl acetate and aqueous fractions (at 500 mg/kg) significantly (p<0.01) reduced the BGL in the streptozotocin induced diabetic model. The crude extract and different solvent fractions also showed a dose-dependent in vitro α-amylase inhibitory activity and improvement of body weight. CONCLUSION: T. brownii crude extract and its solvent fractions showed a significant antihyperglycemic activity in STZ induced diabetic mice, hypoglycemic activity and improvement of oral glucose tolerance in normal mice. Dove 2020-02-20 /pmc/articles/PMC7039073/ /pubmed/32110120 http://dx.doi.org/10.2147/JEP.S240266 Text en © 2020 Alema et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Alema, Niguse Meles Periasamy, Gomathi Sibhat, Gereziher Gebremedhin Tekulu, Gebretsadkan Hintsa Hiben, Mebrahtom Gebrelibanos Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice |
title | Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice |
title_full | Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice |
title_fullStr | Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice |
title_full_unstemmed | Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice |
title_short | Antidiabetic Activity of Extracts of Terminalia brownii Fresen. Stem Bark in Mice |
title_sort | antidiabetic activity of extracts of terminalia brownii fresen. stem bark in mice |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039073/ https://www.ncbi.nlm.nih.gov/pubmed/32110120 http://dx.doi.org/10.2147/JEP.S240266 |
work_keys_str_mv | AT alemanigusemeles antidiabeticactivityofextractsofterminaliabrowniifresenstembarkinmice AT periasamygomathi antidiabeticactivityofextractsofterminaliabrowniifresenstembarkinmice AT sibhatgerezihergebremedhin antidiabeticactivityofextractsofterminaliabrowniifresenstembarkinmice AT tekulugebretsadkanhintsa antidiabeticactivityofextractsofterminaliabrowniifresenstembarkinmice AT hibenmebrahtomgebrelibanos antidiabeticactivityofextractsofterminaliabrowniifresenstembarkinmice |